Regeneron Pharmaceuticals Inc (REGN)

Cash ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cash and cash equivalents	US$ in thousands	2,488,200	2,011,800	1,920,700	2,602,000	2,730,000	2,152,300	1,937,200	3,916,300	3,105,900	3,491,300	3,395,100	3,345,700	2,885,600	3,432,400	2,072,200	1,437,900	2,193,700	1,573,000	1,992,200	2,208,200
Short-term investments	US$ in thousands	6,524,300	7,784,700	7,888,300	7,917,500	8,114,800	7,761,300	6,990,500	5,043,400	4,636,400	3,530,400	4,171,300	3,704,900	2,809,100	2,355,200	1,838,600	2,065,900	1,393,300	1,452,900	1,152,000	1,795,200
Total current liabilities	US$ in thousands	3,944,300	3,661,000	3,508,600	3,580,900	3,423,400	3,598,600	3,104,400	3,100,100	3,141,300	2,879,200	3,033,900	3,007,600	3,932,500	3,714,800	3,732,400	3,217,800	2,697,400	2,337,800	3,702,400	2,055,200
Cash ratio		2.28	2.68	2.80	2.94	3.17	2.75	2.88	2.89	2.46	2.44	2.49	2.34	1.45	1.56	1.05	1.09	1.33	1.29	0.85	1.95

December 31, 2024 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($2,488,200K + $6,524,300K) ÷ $3,944,300K
= 2.28

The cash ratio of Regeneron Pharmaceuticals Inc has shown fluctuations over the past few years. From March 31, 2020, to December 31, 2024, the cash ratio has varied from a low of 0.85 to a high of 3.17.

The cash ratio measures the company's ability to cover its short-term liabilities with its cash and cash equivalents. A higher cash ratio indicates that the company has more liquid assets available to cover its short-term obligations.

In the case of Regeneron Pharmaceuticals Inc, we observe an upward trend in the cash ratio from March 31, 2020, to December 31, 2024. This suggests that the company has been accumulating more cash relative to its short-term liabilities over this period.

A cash ratio above 1.0 indicates that the company has enough cash to cover its current liabilities. Regeneron's cash ratio has mostly remained above 1.0 throughout the observation period, indicating a healthy level of liquidity.

The trend of increasing cash ratio over the years suggests that Regeneron Pharmaceuticals Inc is managing its liquidity well and has a strong ability to meet its short-term obligations with its cash reserves.